Wells Fargo
PCRX icon

Wells Fargo’s Pacira BioSciences PCRX Stock Holding History

Wells Fargo’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-42,300
Closed -$136K – 6514
2017
Q4 		$136K Buy
+42,300
New +$1.68M ﹤0.01% 5170

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's PCRX Position: Q1 2026 in Review

Wells Fargo reduced its Pacira BioSciences (PCRX) stake by 65% in Q1 2026, selling an estimated $762K and leaving 18,190 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #4271.

Wells Fargo first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $110M in Q1 2021. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Wells Fargo held 18,190 shares of Pacira BioSciences worth $411K as of Q1 2026.
  • Wells Fargo sold 34,296 Pacira BioSciences shares in Q1 2026, an estimated $762K.
  • Pacira BioSciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4271 holding.
  • Wells Fargo first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Pacira BioSciences position peaked at $110M in Q1 2021.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.